Skip to main content
Clinical Trials/IRCT20200420047147N1
IRCT20200420047147N1RecruitingPhase 2

Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19

Shahid Beheshti University of Medical Sciences0 sites84 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
84

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Patients who diagnosed with COVID-19 by RT-PCR test
  • Oxygen saturation less than 93%
  • Age more than 18 years old
  • To sign the informed consent form

Exclusion Criteria

  • Chronic kidney disease
  • Acute kidney injury
  • Chronic liver disease
  • pregnancy or breastfeeding
  • Pancreatitis
  • Allergy to Sitagliptin
  • Pemphigus disease history

Investigators

Similar Trials

?Evaluation the effects of Sitagliptin... | Clinical Trial